NCT02713061撤回2 期
An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects
Takeda0 个研究点开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 主要终点
- Seroconversion Rate of HI Antibody Titer (egg-derived antigen)
研究概览
简要总结
This clinical trial is a Phase 2 study of a single subcutaneous injection of TAK-850 for 22 days in healthy Japanese adults.
详细描述
The primary objective of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 for 22 days in healthy Japanese adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
- •The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
- •The participant is a healthy Japanese adult male or female.
- •The participant is aged 20 to 49 years, inclusive, at the time of informed consent.
- •The participant has a body mass index (BMI) between 18.5 and 25.0 kg/m^2, inclusive, at the time of eligibility evaluation.
- •If the participant is a female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
排除标准
- •The participant has received any investigational compound within 4 months prior to the initial injection of study vaccine.
- •The participant has been vaccinated with seasonal influenza vaccine within 6 months prior to the initial injection of study vaccine.
- •The participant has a history of influenza infection within 6 months prior to the initial injection of study vaccine
- •The participant has been vaccinated with TAK-850 (trivalent).
- •The participant is a study site employee, an immediate family member of such an employee, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under duress.
- •The participant has uncontrolled, clinically significant manifestations of neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, endocrine or other disorders, which may impact the ability of the participant to participate or potentially confound the study results.
- •The participant has an oral temperature ≥37.5°C prior to the initial injection of study vaccine on Day
- •The participant has any medically diagnosed or suspected immune deficient condition.
- •The participant has an immune compromising condition or disease, or is currently undergoing a form of treatment or was undergoing a form of treatment that can be expected to influence immune response within 30 days prior to the initial injection of study vaccine. Such treatments include, but is not limited to, systemic or high dose inhaled corticosteroids (>800 μg/day of beclomethasone dipropionate or equivalent; the use of inhaled and nasal steroids that do not exceed this level will be permitted), radiation treatment or other immunosuppressive or cytotoxic drugs.
- •The participant has received antipyretics within 4 hours prior to the initial injection of study vaccine.
- •The participant has a history of Guillain- Barré Syndrome, demyelinating disorders (including acute disseminated encephalomyelitis [ADEM] and multiple sclerosis) or convulsions.
- •The participant has a functional or surgical asplenia.
- •The participant has a rash, other dermatologic conditions or tattoos which may interfere with the evaluation of injection site reaction as determined by the Investigator.
- •The participant has a history of, or is infected with the Hepatitis B Virus (HBsAgs), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).
- •The participant has a known hypersensitivity to any component of TAK-
- •The participant has a history of severe allergic reactions or anaphylaxis.
- •The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the initial injection of study vaccine or is unwilling to agree to abstain from alcohol and drugs throughout the study.
- •The participant has received any blood products (e.g. blood transfusion or immunoglobulin) within 90 days prior to the initial injection of study vaccine.
- •The participant has received a live vaccine within 4 weeks (28 days) or an inactivated vaccine within 2 weeks (14 days) prior to the initial injection of study vaccine.
- •If female, the participant is pregnant or lactating or intending to become pregnant before signing informed consent, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
- •The participant has donated whole blood ≥200 mL within 4 weeks (28 days), ≥400 mL within 12 weeks (84 days), ≥800 mL within 52 weeks (364 days), or blood components within 2 weeks (14 days) prior to the initial injection of study vaccine.
- •The participant has abnormal laboratory values that suggest a clinically significant underlying disease at the assessment prior to the initial injection of study vaccine, or the participant has the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) more than 3 times the upper limits of normal.
- •In the opinion of the investigator or sub-investigator, the participant is unlikely to comply with protocol requirements or is considered ineligible for any other reason.
研究组 & 干预措施
TAK-850 0.5 mL
Experimental
TAK-850 0.5 mL (15 µg of hemagglutinin [HA] antigen per strain), subcutaneous injection, once on Day 1.
干预措施: TAK-850 (Drug)
结局指标
主要结局
Seroconversion Rate of HI Antibody Titer (egg-derived antigen)
时间窗: Day 22
Seroconversion Rate is defined as the percentage of participants with a baseline HI antibody titer of ≥ 10 achieving a minimal 4-fold increase, or baseline HI antibody titer of \< 10 achieving an HI antibody titer of ≥ 40 for each of the four strains (A/H1N1 strain, A/H3N2 strain, B/Yamagata strain, B/Victoria strain).
Number of Participants with Adverse Events
时间窗: Up to Day 22
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment The adverse events will include solicited local and systemic AEs.
Seroprotection Rate of Hemagglutination Inhibition (HI) Antibody Titer (egg-derived antigen)
时间窗: Day 22
Seroprotection Rate is defined as the percentage of participants with HI antibody titer ≥ 40 for each of the four strains (A/H1N1 strain, A/H3N2 strain, B/Yamagata strain, B/Victoria strain).
Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (egg-derived antigen)
时间窗: Day 22
次要结局
- Seroconversion Rate of SRH Antibody Titer (egg-derived antigen)(Day 22)
- Number of Participants who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests(Day 22)
- GMFI in HI Antibody Titer (cell-derived antigen)(Day 22)
- GMT of SRH Antibody Titer (cell-derived antigen)(Day 22)
- Number of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements(Day 22)
- Geometric Mean Titer (GMT) of HI Antibody Titer (egg-derived antigen)(Day 22)
- Seroprotection Rate of Single Radial Hemolysis (SRH) Antibody Titer (egg-derived antigen)(Day 22)
- Seroconversion Rate of HI Antibody Titer (cell-derived antigen)(Day 22)
- Seroprotection Rate of SRH Antibody Titer (cell-derived antigen)(Day 22)
- Seroconversion Rate of SRH Antibody Titer (cell-derived antigen)(Day 22)
- GMFI in SRH Antibody Titer (cell-derived antigen)(Day 22)
- GMFI in SRH Antibody Titer (egg-derived antigen)(Day 22)
- GMT of HI Antibody Titer (cell-derived antigen)(Day 22)
- Seroprotection Rate of HI Antibody Titer (cell-derived antigen)(Day 22)
- GMT of SRH Antibody Titer (egg-derived antigen)(Day 22)
研究者
相似试验
已完成
1 期
A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult SubjectsInfluenzaNCT02111252Takeda55
已完成
2 期
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast CancerEstrogen Receptor Positive Breast CancerNCT02988986The Methodist Hospital Research Institute28
终止
2 期
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on BevacizumabRecurrent GlioblastomaNCT03856099PharmAbcine19
尚未招募
2 期
Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine CarcinomasAdvanced or Metastatic EP-NECNCT05142865Huazhong University of Science and Technology30
已完成
1 期
Low-Dose Ketamine in Children With ADNP SyndromeADNP SyndromeNCT04388774Alexander Kolevzon10